> Detailanzeige

Rieder, Marina [VerfasserIn]; Schubach, Fabian [VerfasserIn]; Schmoor, Claudia [VerfasserIn]; Spee-Mayer, Caroline von [VerfasserIn]; Wengenmayer, Tobias [VerfasserIn]; Rilinger, Jonathan [VerfasserIn]; Staudacher, Dawid [VerfasserIn]; Bode, Christoph [VerfasserIn]; Dürschmied, Daniel Frank [VerfasserIn]; Supady, Alexander [VerfasserIn]

Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Book; Sonderdruck
  • Titel: Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial
  • Beteiligte: Rieder, Marina [VerfasserIn]; Schubach, Fabian [VerfasserIn]; Schmoor, Claudia [VerfasserIn]; Spee-Mayer, Caroline von [VerfasserIn]; Wengenmayer, Tobias [VerfasserIn]; Rilinger, Jonathan [VerfasserIn]; Staudacher, Dawid [VerfasserIn]; Bode, Christoph [VerfasserIn]; Dürschmied, Daniel Frank [VerfasserIn]; Supady, Alexander [VerfasserIn]
  • Erschienen: London: BMJ, 2021
  • Erschienen in: BMJ open ; 11, 1 (2021), e043345
  • Umfang: 1 Online-Ressource (31 Seiten)
  • Sprache: Englisch
  • DOI: 10.1136/bmjopen-2020-043345
  • ISSN: 2044-6055
  • Identifikator:
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract: Introduction Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is a last resort treatment option in patients with severe COVID-19 related acute respiratory distress syndrome (ARDS). Mortality in these critically ill patients is high. Elevated interleukin-6 (IL-6) levels in these severe courses are associated with poor outcome. Extracorporeal cytokine adsorption is an approach to lower elevated IL-6 levels. However, there is no randomised controlled data on the efficacy of cytokine adsorption and its effect on patient outcome in severe COVID-19 related ARDS requiring V-V ECMO support.<br><br>Methods and analysis We here report the protocol of a 1:1 randomised, controlled, parallel group, open-label intervention, superiority multicentre trial to evaluate the effect of extracorporeal cytokine adsorption using the CytoSorb device in severe COVID-19 related ARDS treated with V-V ECMO. We hypothesise that extracorporeal cytokine adsorption in these patients is effectively reducing IL-6 levels by 75% or more after 72 hours as compared with the baseline measurement and also reducing time to successful V-V ECMO explantation. We plan to include a total of 80 patients at nine centres in Germany.<br><br>Ethics and dissemination The protocol of this study was approved by the ethical committee of the University of Freiburg as the leading institution (EK 285/20). Additional votes will be obtained at all participating centres.<br><br>Trial registration numbers NCT04385771 and DRKS 00021248
  • Zugangsstatus: Freier Zugang